Outlook Therapeutics (OTLK) Debt Ratio (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Debt Ratio of 0.96 for Q1 2026, down 44.71% year-over-year from 1.73 in Q1 2025, and down 52.35% quarter-over-quarter from 2.01 in Q4 2025.
Outlook Therapeutics (OTLK) Debt Ratio (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Debt Ratio for 12 consecutive years, with 0.96 the latest figure, recorded in Q1 2026.
- In Q1 2026, Debt Ratio fell 44.71% year-over-year to 0.96; the TTM figure through Mar 2026 stood at 0.96 (down 44.71% YoY), while the FY2025 annual figure was 1.61, up 57.77% from the prior year.
- Debt Ratio slipped to 0.96 in Q1 2026 per OTLK's latest filing, from 2.01 in the prior quarter.
- Across five years, Debt Ratio topped out at 2.01 in Q4 2025 and bottomed at 0.27 in Q2 2022.
- Historically, Debt Ratio has averaged 1.05 across 5 years, with a median of 0.96 in 2026.
- Annual changes were most pronounced in 2023 — Debt Ratio soared 232.0% — and 2026, when it slumped 44.71%.
- Outlook Therapeutics' Debt Ratio stood at 0.51 in 2022, then jumped by 232.0% to 1.69 in 2023, then rose by 7.28% to 1.81 in 2024, then gained by 11.18% to 2.01 in 2025, then sank by 52.35% to 0.96 in 2026.
- Business Quant data shows OTLK's Debt Ratio at 0.96 in Q1 2026, 2.01 in Q4 2025, and 1.61 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.03 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.26 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.47 |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.96 |
| Dec 31, 2025 | 2.01 |
| Sep 30, 2025 | 1.61 |
| Jun 30, 2025 | 1.54 |
| Mar 31, 2025 | 1.73 |
| Dec 31, 2024 | 1.81 |
| Sep 30, 2024 | 1.02 |
| Jun 30, 2024 | 0.69 |
| Mar 31, 2024 | 0.76 |
| Dec 31, 2023 | 1.69 |
| Sep 30, 2023 | 1.10 |
| Jun 30, 2023 | 0.78 |
| Mar 31, 2023 | 0.59 |
| Dec 31, 2022 | 0.51 |
| Sep 30, 2022 | 0.38 |
| Jun 30, 2022 | 0.27 |
| Mar 31, 2022 | 0.34 |
| Dec 31, 2021 | 0.28 |
| Sep 30, 2021 | 0.52 |
| Jun 30, 2021 | 0.35 |